Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1 Altravax.

Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1 Altravax, Inc. Announced today that it has been awarded two SBIR grants totaling $1.2 million from the NIH’s National Institute of Allergy and Infectious Illnesses for research on antibody-inducing vaccines for HIV-1 read more http://l-e-v-i-t-r-a.com/ . A 2009 record from the US has estimated the full total amount of people living with AIDS is currently at over 30 million. The existence of a lot of virus strains and the continuing changing nature of the virus is among the major issues facing the advancement of vaccines for HIV/AIDS. Our past research actions have made significant progress in developing novel vaccine antigens to broadly focus on the numerous HIV-1 strains and we are pleased that the NIH is definitely continuing to aid our analysis on HIV vaccines, stated Dr.

l-e-v-i-t-r-a.com

Altrient C improves skin firmness and elasticity by 32. The results of the trial demonstrated that participants taking Altrient C experienced significantly improved their pores and skin elasticity over the 4-week amount of the clinical trial, in comparison to those taking the placebo. Participants using Altrient C got improved skin firmness and elasticity by 32.7 percent over the same period. After just 14 days, pores and skin firmness and elasticity had improved by 15.1 percent . 100 percent of participants reported that they would change to Altrient C towards their current anti-aging skincare product.